These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2505303)

  • 1. A placebo-controlled trial of L-deprenyl in atypical depression.
    McGrath PJ; Stewart JW; Harrison W; Wager S; Nunes EN; Quitkin FM
    Psychopharmacol Bull; 1989; 25(1):63-7. PubMed ID: 2505303
    [No Abstract]   [Full Text] [Related]  

  • 2. l-Deprenyl in atypical depressives.
    Quitkin FM; Liebowitz MR; Stewart JW; McGrath PJ; Harrison W; Rabkin JG; Markowitz J; Davies SO
    Arch Gen Psychiatry; 1984 Aug; 41(8):777-81. PubMed ID: 6430257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A possible L-deprenyl induced hypertensive reaction.
    McGrath PJ; Stewart JW; Quitkin FM
    J Clin Psychopharmacol; 1989 Aug; 9(4):310-1. PubMed ID: 2504782
    [No Abstract]   [Full Text] [Related]  

  • 4. Deprenyl versus placebo in Parkinson disease: a double-blind study.
    Lieberman AN; Gopinathan G; Neophytides A; Foo SH
    N Y State J Med; 1987 Dec; 87(12):646-9. PubMed ID: 3124027
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical efficacy of deprenyl, a specific inhibitor of MAOB.
    Psychopharmacol Bull; 1983; 19(3):328-42. PubMed ID: 6314420
    [No Abstract]   [Full Text] [Related]  

  • 6. Differential efficacy of L-deprenyl, a selective MAO type-B inhibitor, in endogenous and nonendogenous depression.
    Mann JJ; Frances A; Peselow ED; Gershon S
    Psychopharmacol Bull; 1982 Oct; 18(4):182-4. PubMed ID: 6818606
    [No Abstract]   [Full Text] [Related]  

  • 7. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
    Presthus J; Berstad J; Lien K
    Acta Neurol Scand; 1987 Sep; 76(3):200-3. PubMed ID: 3120487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.
    Mann JJ; Aarons SF; Wilner PJ; Keilp JG; Sweeney JA; Pearlstein T; Frances AJ; Kocsis JH; Brown RP
    Arch Gen Psychiatry; 1989 Jan; 46(1):45-50. PubMed ID: 2491941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylphenidate in mild depression: a double-blind controlled trial.
    Mattes JA
    J Clin Psychiatry; 1985 Dec; 46(12):525-7. PubMed ID: 3905773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. R-(-)-deprenyl in the treatment of end-of-dose akinesia.
    Ulm G; Fornadi F
    J Neural Transm Suppl; 1987; 25():163-72. PubMed ID: 3123603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease.
    Golbe LI; Duvoisin RC
    J Neural Transm Suppl; 1987; 25():123-9. PubMed ID: 3123598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation.
    Mendlewicz J; Youdim MB
    Br J Psychiatry; 1983 May; 142():508-11. PubMed ID: 6409196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW; Langston JW
    J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial.
    Rascol O; Montastruc JL; Senard JM; Demonet JF; Simonetta M; Rascol A
    Neurology; 1988 Sep; 38(9):1387-91. PubMed ID: 3137488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychopharmacologic validation of atypical depression.
    Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison W; Rabkin JG; Tricamo E; Markowitz JS; Klein DF
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):22-5. PubMed ID: 6376483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of placebo-controlled trials with bupropion.
    Zung WW
    J Clin Psychiatry; 1983 May; 44(5 Pt 2):104-14. PubMed ID: 6406436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical effects of L-deprenyl in atypical depressives.
    Liebowitz MR; Karoum F; Quitkin FM; Davies SO; Schwartz D; Levitt M; Linnoila M
    Biol Psychiatry; 1985 May; 20(5):558-65. PubMed ID: 3921065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of the effectiveness of combined (L-dopa + Jumex) therapy based on a multicentric double blind study].
    Tariska I; Gallai M
    Orv Hetil; 1983 Sep; 124(38):2309-14. PubMed ID: 6415577
    [No Abstract]   [Full Text] [Related]  

  • 19. Is loss of antidepressant effect during continuation therapy related to placebo effect?
    Harrison W; Stewart JW; McGrath PJ; Tricamo E; Quitkin FM
    Psychopharmacol Bull; 1988; 24(1):9-13. PubMed ID: 3290953
    [No Abstract]   [Full Text] [Related]  

  • 20. L-deprenyl plus L-phenylalanine in the treatment of depression.
    Birkmayer W; Riederer P; Linauer W; Knoll J
    J Neural Transm; 1984; 59(1):81-7. PubMed ID: 6425455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.